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Surfactant protein A (SP-A) provides surfactant stability, first line host defense, and lung
homeostasis by binding surfactant phospholipids, pathogens, alveolar macrophages
(AMs), and epithelial cells. Non-primates express one SP-A protein whereas humans
express two: SP-A1 and SP-A2 with core intra- and inter-species differences in the
collagen-like domain. Here, we used macrophages and solid phase binding assays to
discern structural correlates of rat (r) and human (h) SP-A function. Binding assays using
recombinant rSP-A expressed in insect cells showed that lack of proline hydroxylation,
truncations of amino-terminal oligomerization domains, and site-directed serine (S) or
alanine (A) mutagenesis of cysteine 6 (C6S), glutamate 195 (E195A), and glutamate
171 (E171A) in the carbohydrate recognition domain (CRD) all impaired SP-A binding.
Replacement of arginine 197 with alanine found in hSP-A (R197A), however, restored
the binding of hydroxyproline-deficient rSP-A to the SP-A receptor SP-R210 similar
to native rat and human SP-A. In silico calculation of Ca++ coordination bond length
and solvent accessibility surface area revealed that the “humanized” R197A substitution
alters topology and solvent accessibility of the Ca++ coordination residues of the CRD
domain. Binding assays in mouse AMs that were exposed to either endogenous SP-A
or hSP-A1 (6A2) and hSP-A2 (1A0) isoforms in vivo revealed that mouse SP-A is a
functional hybrid of hSP-A1 and hSP-A2 in regulating SP-A receptor occupancy and
binding affinity. Binding assays using neonatal and adult human AMs indicates that the
interaction of SP-A1 and SP-A2 with AMs is developmentally regulated. Furthermore, our
data indicate that the auxiliary ion coordination loop encompassing the conserved E171
residue may comprise a conserved site of interaction with macrophages, and SP-R210
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specifically, that merits further investigation to discern conserved and divergent SP-A
functions between species. In summary, our findings support the notion that complex
structural adaptation of SP-A regulate conserved and species specific AM functions
in vertebrates.
Keywords: alveolar macrophages, binding, lung, surfactant protein A, receptor
INTRODUCTION
Surfactant protein A (SP-A) is the most abundant lipid binding
and immune-surveillance component of pulmonary surfactant.
SP-A belongs to the collectin family of proteins consisting of
four structural domains that include an amino-terminal tail,
a collagen-like domain (CDM) with Gly-X-Y repeats, an α-
helical coiled-coil neck domain with heptad repeats, and a
Ca++-dependent carbohydrate recognition domain (CRD) (1–
3). The neck and collagen-like domains of SP-A trimerize
and assemble into higher order deca-octamers via inter-
chain disulfide bonds in the amino-terminal tail and non-
covalent interactions between trimers. Binding to extracellular
ligands depends on the neck-CRD trimer and high avidity
multivalent binding of the SP-A deca-octamer. Crystallographic
and molecular modeling studies of the rat SP-A CRD revealed
that conformational flexibility of the Ca++ coordination site
and CRD surface loops impart versatility in the ability of
SP-A to bind structurally diverse endogenous and pathogen-
derived ligands (2, 4–7). The interaction of SP-A with AMs
and epithelial cells is receptor-mediated (8–10). Deletion, site-
directed mutagenesis, and ligand competition studies showed
that the amino-terminal and collagen-like domains influence
receptor occupancy and functional responses in alveolar type
II epithelial cells and macrophages, and interaction of the
CRD domain with surfactant phospholipids (10–16). SP-A
binds dipalmitoyl phosphatidylcholine, the major surfactant
phospholipid, that is required for the formation of tubular myelin
from secreted lamellar bodies, contributes to the adsorption
of surface active phospholipids at the air-liquid interface, and
facilitates turnover of spent surfactant vesicles by alveolar type
II epithelial cells through the p63 receptor (7, 17–21). In
host defense, SP-A binds different pathogen ligands such as
the lipid A portion of lipopolysaccharide on Gram-negative
bacteria (7), surface proteins and glycolipids on gram positive
bacteria (22), mycobacteria (23, 24), and fungi (25, 26). These
interactions facilitate pathogen clearance through agglutination,
opsonization, and direct killing (22, 26–29). SP-A enhances
opsonic and non-opsonic phagocytosis (22, 30–32), and shapes
pathogen-dependent polarization of inflammatory responses
Abbreviations: AMs, alveolar macrophages; BAL, bronchoalveolar lavage; CDM,
collagen-like domain; CLL, carbohydrate, lipids, LPS binding site; CRD,
carbohydrate recognition domain; GEC, Glycine Glutamate Cysteine; GER,
Glycine Glutamate Arginine; MDLG, Methionine Aspartate Leucine Glycine;
NCRD, coiled-coil neck and CRD domain; PCPP, Proline Cysteine Proline Proline;
SP-A, surfactant protein A; rSP-A, native rat SP-A; hSP-A, native human SP-
A; hSP-A1 6A2, human SP-A isoform 1 variant 6A2; hSP-A2 1A0, human SP-A
isoform 2 variant 1A0; rSP-Ahyp, hydroxyproline-deficient recombinant rat SP-A;
SP-R210, SP-A receptor 210; Myo18A, Myosin 18A.
through the SP-R210 SP-A receptor (aka Myo18A or CD245)
(22, 27, 33) in macrophages.
Unlike non-primate amniotes (34), humans express two SP-A
protein isoforms, SP-A1 and SP-A2 encoded by different genes
SFTPA1 and SFTPA2 (35), and each gene has been identified
with several variants. The hSP-A1 and hSP-A2 proteins and their
respective variants differ at four core amino acids in the collagen-
like domain and the variants of each gene are distinguished
among themselves by additional amino acid differences present
in domains other than the collagen-like domain (36–38).
SP-A1 and SP-A2 differentially modulate macrophage function
(39–41) and in suppressing development of idiopathic interstitial
pneumonia, fibrosis, and cancer (42–45). Moreover, significant
differences have been observed among SP-A1 and SP-A2 variants
in survival after infection and lung function (46, 47). The
presence of both proteins is required for tubular myelin
formation, supra-trimeric assembly of SP-A oligomers, and
optimal function of surfactant (21, 48, 49) and one SP-A gene is
sufficient to exert these functions in lower vertebrates (19, 50, 51).
Both human and rodent SP-As have a discrete kink peptide in
the middle of the CDM that confers conformational flexibility,
contributes to the quaternary organization of higher order SP-
A oligomers, and spatial separation of CRD domains (52–54).
The kink sequence is conserved between SP-A1 and SP-A2 but
different from rodent SP-A; PCPP in human SP-As andMGLP in
rodents (34, 54). The kink peptide and a unique GEC collagen
triplet in SP-A1 (GER in SP-A2) result in 2 cysteine residues
in the CDM of SP-A1 compared to 1 in SP-A2 and none in
rodent SP-A. The GEC triplet contributes to distinct oligomeric
structures in SP-A1 and the two proteins distribute differently
in interfacial surfactant films (48, 49, 55). Compared to SP-
A2, SP-A1 improved the biophysical activity of surfactant in
lowering surface tension and resistance to inhibition by serum
(56). Recombinant SP-A1 lacking the ability to form oligomers,
however, retains anti-inflammatory effects on macrophages (57,
58), whereas SP-A2 variants compared to SP-A1 have been shown
to exhibit higher activity in bacterial phagocytosis by AMs (59)
and cytokine production in a macrophage-like cell line (39,
60).To better understand SP-A function we used binding assays
and molecular modeling to define molecular and functional
attributes in rodent and human SP-A.
MATERIALS AND METHODS
Animals
Wild type (SP-A+/+) C57BL/6J mice were purchased from
JAX labs and bred locally. Transgenic SP-A−/− and humanized
mSftpa−/−,hSFTPA1(6A2) and mSftpa−/−,hSFTPA2(1A0) mice were
generated as described previously (21). Sprague-Dawley rats were
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obtained from Harlan. All animal procedures were performed
under IACUC approved protocols.
Production and Purification of
Recombinant Proteins
Recombinant rat SP-A proteins were synthesized in insect Sf9
cells via baculovirus expression of rat SP-A WT cDNA or
mutant cDNAs generated by nested deletion or site directed
mutagenesis as described in detail previously (25, 61). The
present studies utilized rat SP-A with C6S, E171A, E195A,
R197A, and D215A point mutations and deletion mutants
lacking both amino terminal and collagen-like domains (1N1-
G80), the collagen-like domain (1G8-G80), kink (1G8-
G40) and proximal (1G40-G80) halves of the collagen-like
domain. Recombinant rat SP-A proteins were isolated by
affinity chromatography over mannose-Sepharose. Native rat
SP-A was isolated from the bronchoalveolar lavage (BAL) of
Sprague-Dawley rats 4 weeks after instillation of 40 mg/Kg
of silica-induced alveolar proteinosis Rat BAL surfactant was
separated by NaBr-density gradient centrifugation followed
by delipidation, affinity and gel exclusion chromatography
(12, 19, 25, 61–64). Native human SP-A was isolated from
discarded alveolar proteinosis BAL by sequential isobutanol/β-
octylglucoside extraction, repeated precipitation/solubilization
in 20mM CaCl2/EDTA, and extensive dialysis in 5mM HEPES,
pH 7.4 (32). Recombinant human SP-A1 (variant 6A2) and
SP-A2 (variant 1A0) were expressed in CHO-K1 cells via the
pEE14 expression vectors (39). SP-A1 and SP-A2 secreted in
media were purified by affinity chromatography over mannose-
Sepharose and gel filtration chromatography over Superose 6
(39). The purity of rat and human proteinosis SP-A was >95%
and recombinant human SP-A1 and SP-A2 was >95% pure
as assessed by 1 and/or 2-dimensional SDS-PAGE (39, 65),
respectively. All SP-A preparations contained negligible amounts
of bacterial endotoxin lipopolysaccharide below 0.1 pg/mg of
protein as assessed by the Limulus Amoebocyte Lysate assay.
Isolation of Alveolar Macrophages From
Transgenic Mice and Human Lung
Mouse AMs were isolated by BAL using five sequential
intratracheal instillation of 0.5mL PBS/1mM EDTA for a total
of 2.5mL. The BAL was centrifuged at 250 × g for 10min to
pellet the macrophages. The macrophages were washed once
in PBS, counted, and then suspended in iodination blocking
buffer. Human AMs were isolated from donated human lungs
which were rejected for transplant ex vivo as described previously
(66, 67). All procedures were approved by the Penn State
College of Medicine Institutional Review Board. Cell purity
was assessed microscopically after cytospin centrifugation and
HEMA-3 differential staining (29).
Molecular Dynamics Simulation
The starting coordinates for molecular dynamics (MD)
simulations were obtained from the recombinant rat SP-A
crystal structure 1R13 (4) (http://www.rcsb.org/pdb/explore.
do?structureId=1r13) consisting of the neck and CRD domain
with a mutation at the glycosylation site consensus asparagine
187 (N187S) and lacking the amino-terminal and collagen-like
domains (1N1-80) using Swiss-Pdb Viewer (68). Molecular
dynamics simulations were carried out as described previously
(69). We tested the impact of alanine point mutations in the
primary Ca++ coordination residues of the CRD carbohydrate-
lipid-LPS (CLL) binding pocket, E195A, R197A, N214A, and
D215A, and E171A in the auxiliary metal ion coordination loop
on Ca++- coordination bond length and solvent accessibility
surface area. All residues tested are conserved between rodent
and human SP-A, except for R197 which is naturally substituted
by an alanine in both human SP-A1 and SPA2.
Sequence Alignment and Numbering of
Rodent and Human SP-A
Sequence alignments were performed using ClustalW (70, 71)
(Figure 1). The amino acid alignment and location of Ca++-
coordination residues of rat SP-A and human SP-A2 (variant
1A0) are shown on Figure 1A and part of the CDMon Figure 1B.
The numbering of amino acid residues on Figure 1A is based on
the mature rat SP-A after cleavage of the respective signal peptide
between residues C20-N21 or as stated otherwise (Uniprot
Accession No: P08427) (72, 73). In humans, although the signal
peptide cleavage has been shown to affect a few amino acids (74),
here we based the numbering on one of the cleaved variants
in C20-E21 of the SP-A2 variant 1A0 (Uniprot Accession No:
Q8IWL1). For the CDM alignments numbering is from the start
of respective signal sequences (Figure 1B) to avoid confusion
with differences in amino-acid numbering for rat and human SP-
A1 and SP-A2 in the literature. The numbering of all rat SP-A
point and deletion mutants is based on the mature rat peptide.
Macrophage and Solid Phase Binding
Assays
Macrophage binding assays were performed using mouse or
human AMs, or the RAW264.7 macrophage cell line and 125I-
labeled SP-A as described in detail previously (10, 32). The
purified His-tagged SP-A binding neck domain of SP-R210 (32,
75) was used in solid phase binding assays with SP-A. Flat
bottomed 96 well ELISA plates were treated with 0.1M Na2CO3,
pH9.3, and coated with 10µg/mL of purified nSP-R210, and
blocked in 0.1% BSA. Recombinant rat SP-A, native rat, or
human SP-A1 or SP-A2 were added at increasing concentration
in SP-A binding buffer (HBSS not containing phenol red, 20mM
HEPES (pH 7.4), 1mM CaCl2, 0.2mMMgCl2, 1% bovine serum
albumin) and incubated at 37◦C in a humidified chamber. Plates
were washed in binding buffer, incubated with HRP-conjugated
anti-rat affinity purified polyclonal rabbit anti-SP-A antibody for
1 hr. at room temperature, and then washed. Bound antibody
was visualized using 3, 3′, 5, 5′-tetramethylbenzidine (TMB)HRP
substrate at 450 nM.
Data Analysis
Graphical analyses of binding data were performed with
GraphPad Prism software (GraphPad Software, San Diego,
CA). Binding data were analyzed by non-linear regression of
saturation curves fitted to a single site equilibrium binding
equation using Prism software to calculate the number of SP-
A binding sites/cell (Bmax) and binding affinities (Kd). The hill
equation embedded in Prizm software was used to calculate
Frontiers in Immunology | www.frontiersin.org 3 November 2019 | Volume 10 | Article 2613
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FIGURE 1 | Partial sequence alignment of the CRD (A) and CDM (B) domains of rodent and human SP-A. (A) Alignment of the CRD domains of human SP-A2 1A0
variant (hSP-A2) and rat SP-A carbohydrate recognition domain. Amino acid numbering is based on the mature peptide of rat SP-A. Arrows point to
Ca++-coordination residues. (B) Alignment of the collagen-like domains of human SP-A1 (6A2) (hSP-A1) and hSP-A2 1A0 variant, mouse SP-A (mSP-A), and rat SP-A
(rSP-A). All alignments are made to hSP-A2 (1A0). The aligned sequences shown encompass the kink peptide (bolded residues 66–50) to the end of the CDM. Arrows
point to core amino acids in the CDM that distinguish SP-A1 and SP-A2; the numbering is based on the precursor molecule. Residues shown in italicized red font
show the sequence of embedded integrin binding motifs in the CDM. Sequence alignments were performed using ClustalW.
the Hill coefficient of cooperativity for human SP-A binding to
murine and human alveolar macrophages.
RESULTS
Spatial Interaction of Oligomerization and
CRD Domains of SP-A
We used deletion and point mutants of insect cell expressed rat
SP-A to map SP-A binding to macrophages and recombinant SP-
R210 compared to native human or rat SP-A isolated from BAL.
Insect cell expressed SP-A lacks proline hydroxylation of Gly-X-
Pro repeats in the CDM of SP-A (rSP-Ahyp) and also exhibits
an altered pattern of glycosylation (61). Hydroxyproline imparts
thermal stability that influences the degree of oligomerization of
the collagen-like domain of SP-A (61). Saturation binding assays
demonstrated that lack of hydroxyproline reduced SP-A binding
potential to both macrophages (Figures 2A,C,E,F, Table 1) and
recombinant SP-R210 (Figures 3A–D, Table 2) as demonstrated
by 3–9 fold decreases in both maximal binding (Bmax) and
binding affinity (Kd) compared to native SP-A.
Deletion and site-directed mutagenesis were then used to
assess the effect of the amino-terminal and CDM oligomerization
domains on the binding of rSP-Ahyp (Figures 1A,B, 2A,
Tables 1, 2). Complete CDM deletion (rSP-Ahyp,1G8−G80)
impaired binding to both macrophages and SP-R210 compared
to rSP-Ahyp. Point mutation of cysteine 6 to serine in the amino
terminal peptide (rSP-Ahyp,C6S) diminished Bmax with similar
binding affinity to both macrophages and SP-R210 compared
to rSP-Ahyp. The partial CDM deletion rSP-Ahyp,1G8−G40
and rSP-Ahyp,1G40−G80 mutants had increased high affinity
binding at reduced Bmax in macrophages compared to rSP-
Ahyp. The rSP-Ahyp,1G40−G80 mutant, however, exhibited
reduced affinity to SP-R210, whereas rSP-Ahyp,1N1−G80
bound SP-R210 with increased affinity compared to rSP-
Ahyp. The Hughes-Klotz double reciprocal plots (Figures 2B,F,
3B) indicated negative cooperativity for rSP-Ahyp, native
SP-A (Figure 2F), and the partial CDM deletion mutants
rSP-Ahyp,1G8−G40 and rSP-Ahyp,1G40−G80 compared to non-
interacting binding sites for rSP-Ahyp,C6S, rSP-Ahyp,1G8−G80 and
rSP-Ahyp,1N1−G80, indicating that oligomerization modulates
the binding behavior of SP-A. Mutants to examine the role
of the neck coiled-coil domain are not available. Molecular
dynamics simulations with and without the coiled-coil domain
showed as the CRD alone did not equilibrate in silico as
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FIGURE 2 | Impact of domain deletion and site directed mutagenesis on SP-A binding to macrophages. Binding assays used Raw264.7 macrophages in suspension.
Cells were incubated with increasing concentrations of either radiolabeled recombinant rat SP-A proteins (A–D) or human SP-A (E,F) purified from alveolar proteinosis
lavage. Binding data were fitted by non-linear regression to generate binding isotherms (A,C,E) or transformed into double reciprocal plots to evaluate SP-A binding
behavior (B,D,F). Assays were carried out at 4◦C for 1.5 h. at the 50,0000 cells/assay. Bound SP-A was separated by centrifugation over a silicon oil mixture to
separate bound from free SP-A. Assays were performed in triplicate and data pooled from 2 independent experiments. Data shown are Means ± SE.
TABLE 1 | Parameters of SP-A binding to macrophages.
Protein Bmax
(ng/50,000 cells)
Kd (nM)
hSP-A 52.83 ± 0.01 6.94 ± 0.002
rSP-Ahyp 8.94 ± 2.71 13.60 ± 6.60
rSP-Ahyp,1N1−G80 7.12 ± 1.80 68.57 ± 20.59
rSP-Ahyp,1G8−G40 4.68 ± 1.14 16.10 ± 6.90
rSP-Ahyp,1G40−G80 3.21 ± 0.93 7.84 ± 4.04
rSP-Ahyp,1G8−G80 8.58 ± 7.10 34.42 ± 39.81
rSP-Ahyp,E171A 24.96 ± 6.00 33.56 ± 11.35
rSP-Ahyp,E195A 5.05 ± 4.64 13.22 ± 21.16
rSP-Ahyp,D215A 19.38 ± 5.82 36.29 ± 19.56
rSP-Ahyp,C6S 1.01 ± 0.25 15.62 ± 6.52
indicated by the increasing root mean square deviation
(RMSD) of the CRD α-carbon atoms compared to the NCRD
(Figure 4).
We then examined the effect of alanine (A) mutagenesis of
residues that influence geometry and Ca++ coordination in the
CRD domain (4, 5) using binding assays and MD simulations
(Table 1). Compared to the crystal structure, the MD simulations
indicate that the side chain carbonyl for asparagine (N) 214 and
backbone carbonyl of aspartate (D) 215 occupy spaces further
away from Ca++ in the WT CRD. The side chain hydroxyl of
D215 and both oxygens in the E202 side chain are oriented closer
to the Ca++ ion (Table 3). The invariant glutamate 171 (E171)
influences Ca++ coordination of the E202 residue side chain,
conformation of the double-loop structure surrounding the CRD
carbohydrate binding pocket via a side-chain salt bridge with
lysine K203, and coordination of an auxiliary ion (4, 5). The
E171A substitution mutant (rSP-Ahyp,E171A) exhibited increased
binding at high concentrations to macrophages compared
to rSP-Ahyp (Figure 2C). The double-reciprocal Hughes-Klotz
plot (76) of rSP-Ahyp,E171A showed strongly increased negative
cooperativity compared to rSP-Ahyp (Figure 2D), suggesting
abortive interaction with macrophages at low concentration.
Binding to SP-R210 was not be determined. The E202 side
chain of rSP-Ahyp,E171A did not coordinate Ca++, consistent
with crystallographic data (4). The average surface area solvent
accessibility (SASA) of the Ca++ ion and Ca++ coordination
amino acids, however, was not altered by the E171A substitution
compared to WT (Tables 4, 5). In previous studies, mutation
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FIGURE 3 | Impact of domain deletion and site-directed mutagenesis on SP-A binding to SP-R210. The recombinant SP-A binding domain of SP-R210 was coated
onto microtiter well plates, and incubated with increasing concentration of indicated recombinant rat SP-A proteins (A–D), or native human or rat SP-A proteins (C,D).
Bound protein was detected using an HRP-conjugated SP-A antibody. Binding data were fitted by non-linear regression to generate binding isotherms (A,C) or
transformed into double reciprocal plots to evaluate SP-A binding behavior (B,D). Assays were performed in duplicate or triplicate and data pooled from 2
independent experiments. Data shown are Means ± SE.
TABLE 2 | Parameters of SP-A binding to SP-R210.
Protein Bmax (A405) Kd (nM)
hSP-A 3.78 ± 0.08 0.90 ± 0.12
rSP-A 3.08 ± 0.11 1.76 ± 0.28
rSP-Ahyp 0.86 ± 0.13 7.81 ± 2.60
rSP-Ahyp,1N1−G80 0.82 ± 0.02 3.19 ± 0.27
rSP-Ahyp,1G8−G40 0.92 ± 0.20 4.54 ± 2.60
rSP-Ahyp,1G40−G80 1.32 ± 0.40 24.77 ± 11.70
rSP-Ahyp,1G8−G80 0.57 ± 0.31 27.80 ± 22.75
rSP-Ahyp,E195A 0.82 ± 0.43 36.27 ± 26.02
rSP-Ahyp,R197A 3.31 ± 0.08 9.64 ± 2.03
rSP-Ahyp,D215A 2.01 ± 0.18 10.10 ± 1.88
rSP-Ahyp,C6S 0.32 ± 0.07 8.66 ± 1.77
of residues E195 (rSP-Ahyp,E195A) and D215 (rSP-Ahyp,D215A),
two invariant residues that coordinate Ca++, demonstrated
critical roles in Ca++-dependent binding and aggregation of
DPPC, and binding to alveolar type II epithelial cells (13). E195
coordinates Ca++ via its side chain oxygens. Here, the binding
affinity of the rSP-Ahyp,E195A mutant could not be accurately
determined from the binding curves (Table 1). The double-
reciprocal plot of rSP-Ahyp,E195A binding data, however, revealed
FIGURE 4 | Dynamics of CRD and neck-CRD domains. Plot of root mean
square deviation (RMSD) of α-Carbon atoms over time for CRD (red trace) and
neck-CRD (black trace).
atypical sigmoidal behavior suggesting interaction with low and
high affinity binding sites in macrophages (Figure 2D), whereas
this mutant exhibits negative cooperativity with recombinant
SP-R210 (Figure 3D). In the E195A substitution, the R197
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TABLE 3 | Calcium coordination bond length in WT and mutant rat SP-A NCRD.
X-ray
(1N1-G80)
WT NCRD
(1N1-G80)
E171A E195A R197A N214A D215A
E195:OE1 2.43 2.14 ± 0.05 2.15 ± 0.06 2.73 ± 0.71 2.17 ± 0.07 2.19 ± 0.07
E195:OE2 3.73 3.77 ± 0.2 3.63 ± 0.36 2.64 ± 0.7 3.32 ± 0.53 2.31 ± 0.13
R197:O 2.87 2.3 ± 0.09 2.27 ± 0.07 6.93 ± 0.32 2.25 ± 0.08 2.28 ± 0.09 5.82 ± 1.03
N214:ON1 2.46 4.61 ± 0.58 4.62 ± 0.39 5.12 ± 0.50 2.25 ± 0.08 4.15 ± 0.41
D215:O 2.34 3.75 ± 0.22 4.2 ± 0.28 3.63 ± 0.70 2.77 ± 0.52 4.54 ± 0.26 2.42 ± 0.26
D215:OD1 2.27 2.22 ± 0.08 2.19 ± 0.07 2.11 ± 0.05 2.13 ± 0.05 2.19 ± 0.07
D215:OD2 4.03 2.25 ± 0.1 2.29 ± 0.13 3.95 ± 0.17 4.09 ± 0.17 2.27 ± 0.12
E202:OE1 5.91 3.91 ± 0.2 2.22 ± 0.09 5.11 ± 1.07 4.25 ± 0.12 2.23 ± 0.12
E202:OE2 4.25 2.13 ± 0.05 2.23 ± 0.09 6.28 ± 0.51 2.14 ± 0.06 2.35 ± 0.42
TABLE 4 | Effect of CRD mutation on binding pocket water occupancy.
Protein % of time within 3Å SASA of Ca++
1 2 3 4
WT 100% 100% 4.92 ± 1.89
E171A 100% 98% 5.07 ± 2.32
E195A 100% 73% 73% 67% 27.74 ± 5.03
R197A 100% 100% 7.02 ± 1.62
N214A 10% 98% 6.12 ± 2.38
D215A 100% 100% 87% 11.10 ± 2.57
X-Ray + +
backbone carbonyl moved 4.63 Å away from Ca++, and also
altered the orientation of asparagine (N) 214, D215, and E202
side chains relative to the Ca++ ion (Table 3 and Figures 5A,B).
These changes were accompanied by increased H2O occupancy
and average SASA of the Ca++ coordination site residues
(Tables 4, 5), suggesting that H2O modifies the ligand binding
properties of this mutant. The rSP-Ahyp,D215A mutant, on the
other hand, displayed increased Bmax and low affinity non-
cooperative binding compared to rSP-Ahyp (Figures 2C, 3C and
Tables 1, 2). The D215 residue contributes both its side chain
and peptide bond carbonyl to Ca++-coordination. The in silico
calculations showed that the D215 backbone carbonyl moves
closer to Ca++ by 1.33 Å when the side chain is replaced
by Alanine (Table 3). The D215A substitution also influenced
the orientation of E195 and E202 side chains, Ca++ proximity
of the R197 carbonyl, and increased Ca++-H2O occupancy
(Tables 3–5). The arginine (R) 197 residue, which coordinates
Ca++-H2O occupancy via its peptide bond carbonyl, is naturally
switched with alanine in human SP-A. Interestingly, the R197A
substitution increased the binding of rSP-Ahyp,R197A to SP-R210
similar to the level of native rat and human SP-A, neutralizing the
negative impact of proline hydroxylation deficiency in the CDM
(Figure 3C and Table 2). The computational analysis revealed
that the R197A switch brings the hydroxyl oxygens of E195
and N214 side chains and peptide chain carbonyl oxygen of
D215 closer to Ca++ by 1-2.5 Å while the hydroxyl oxygen of
D215 and both side chain oxygens of E202 orient away from
TABLE 5 | Effect of mutation on SASA of Ca++ coordination residues.
Protein
WT 227.38 ± 23.94
E171A 192.57 ± 20.65
E195A 220.28 ± 16.24
R197A 106.33 ± 11.50
N214A 194.83 ± 15.71
D215A 231.82 ± 28.77
X-Ray 265.76
Ca++ (Table 3). The hydroxyl oxygen of the D215 side chain
rotated the farthest, 4.15 Å away from Ca++ compared to WT.
These adjustments in Ca++ coordination are accompanied by
>50% decrease in hydrophilic SASA of the Ca++ coordination
shell from 227.38 ± 23.94 to 106 ± 11.50 Å2 of WT and rSP-
Ahyp,R197A, respectively, suggesting a more compact structure of
the “humanized” CRD (Tables 4, 5).
Cross-Species Paracrine Effects of Mouse
and Human SP-A on AMs
We took advantage of previously developed “humanized” SP-A
transgenic mice to determine the impact of SP-A isoforms on
AM binding phenotype. The hSP-A1 and hSP-A2 isoforms were
expressed in the lungs of SP-A−/− mice. Binding assays were
carried out in AMs from WT (SP-A+/+), SP-A-deficient (SP-
A−/−), or SP-A−/− mice carrying either expression of human
SP-A genes SFTPA1 (6A2) or SFTPA2 (1A0) via the alveolar
epithelial Sftpc promoter (21). The coding sequences of 6A2
and 1A0 hSP-A1 and hSP-A2 variants, respectively, differ in
four core amino acids in their collagen-like domain plus amino
acids 19 and 91 (77), based on the numbering of the precursor
molecule. The binding assays in Figures 6A–D and Table 6 show
that in vivo expression of hSP-A2 resulted in ligand-induced
upregulation of hSPA2 binding to AMs compared to SP-A−/−
and hSP-A1 exposed AMs as demonstrated by the 2-2.5 increase
in Bmax (Table 6). hSP-A2 also improved the binding potential
of hSP-A1 by increasing binding affinity. hSPA1 did not bind SP-
A−/− AMs and its expression alone induced only low affinity
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FIGURE 5 | The E195A substitution alters the Ca++-coordination mode in the CLL binding pocket. Ribbon diagrams depicting the geometry of Ca++-coordination
site of the native (A) and mutant E195A NCRD (B). Red arrows point to the carbonyl oxygen in the R197 residue.
binding of hSPA1 compared to high affinity binding for hSP-
A2, although at lower Bmax compared to the hSPA2 expression.
High affinity binding of hSP-A1 was observed only in AMs from
hSP-A2 or WT mice. The endogenous SP-A, however, had a
hybrid effect enhancing both binding affinity and Bmax with
positive cooperativity. Compared to one another, the Bmax of
hSP-A1 binding was 2–3-fold lower than that of hSP-A2 binding
to murine AMs, indicating that the CDM is responsible for
differences in receptor binding capacity of hSP-A isoforms with
identical CRD.
To address differences in receptor binding properties between
mouse and human AMs, we performed binding assays with
human AMs obtained from donated non-transplanted lung from
a 6 month old newborn and a 20 year old adult individual.
Figure 6E and Table 7 demonstrate that the Bmax for hSP-A2
was 3-fold higher in adult AMs than newborn AMs compared to
a 1.6-fold increase for hSP-A1. The binding affinities were similar.
Non-linear regression analysis of saturation data (Figure 6E,
Table 7) revealed a change from non-cooperative to cooperative
binding in newborn vs. adult AMs, respectively. The binding
assays in mouse AMs exposed to endogenous or human SP-As
in vivo indicate that hSP-A2 and endogenous mouse SP-A
shaped the positive cooperativity binding phenotype of AMs
(Figures 6A,B, andTable 6), whereas hSP-A1 did not. Additional
assays in the presence of EDTA revealed that 30–50% of Bmax for
hSP-A1 and hSP-A2 represent Ca++-independent binding sites
(Figure 6F). The cooperative binding behavior in the absence
of Ca++ was not altered. The binding affinities for both hSP-A
isoforms were higher in newborn AMs compared to adult
AMs, suggesting developmental regulation of SP-A binding in
postnatal life.
DISCUSSION
The present studies refine our understanding of structural
features that modulate rodent and human SP-A binding
properties to macrophages. To our knowledge, the present
study is the first direct comparison of rodent and human SP-
A variants. Nested deletion mutagenesis, point mutations, and
in silico simulations of rat SP-A indicated that high affinity
binding to macrophages or SP-R210 depends on inter-domain
interactions and binding sites in the CDM and CRD domains.
Previous studies reported that the CDM of rat and human SP-
A mediates binding to macrophages (10, 14). Here, deletion
of the entire CDM abolished high affinity binding to both
macrophages and SP-R210, whereas the rSP-Ahyp,1N1−80 mutant
lacking both domains displayed low affinity binding relative
to SP-Ahyp, suggesting that the amino-terminal peptide plays
a conformational role in modulating binding distally. Partial
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FIGURE 6 | Murine and human SP-A variants are paracrine regulators of SP-A binding to alveolar macrophages in postnatal lung. Binding assays were carried out
with alveolar macrophages obtained from either murine lung (A–D) or human lung (E,F) using radiolabeled human SP-A1 or SP-A2 in the presence (A,C,E) or
absence of calcium (B,D,F). Alveolar macrophages from murine lungs (A–D) were obtained from WT (SP-A+/+), SP-A-deficient (SP-A−/−), or humanized mice
expressing either SP-A1 variant 1A0 (SP-A−/−,hSFTPA2(1A0)), or SP-A2 variant 6A2 (SP-A−/−,hSFTPA2(6A2)) in the absence of endogenous murine SP-A (Sftpa). Human
alveolar macrophages were obtained from 6 month (E) and 20 years old (F) rejected transplant lungs. Assays were carried out at 4◦C for 1.5 h at 50,0000 cells/assay.
Bound SP-A was separated by centrifugation over a silicon oil mixture. Assays were performed in duplicate and data pooled from 2 independent experiments.
Alveolar macrophages from mouse lungs were pooled from 10 mice per genotype to obtain sufficient number of cells per experiment. Binding isotherms were
generated using Prizm software by non-linear regression analysis using the Hill equation. Data shown are Means ± SE.
CDM deletion, however, indicated that the amino-terminal half
of the CDM that follows the kink peptide binds macrophages
and SP-R210. On the other hand, site directed mutagenesis in the
CRD domain showed that the E171A, D215A, and E195A point
mutants altered binding behavior. All three mutations altered the
conformation of Ca++ coordination and, furthermore, D215A
and E195A increased accessibility to solvent. The E171 residue
stabilizes the conformation of the CRD surface loops, while D215
and E195 are critical for binding to carbohydrates, lipids, and
LPS (4–7). The present findings support the notion that the
SP-R210 binding site on the CRD domain lies outside the CLL
binding pocket.
Species adaptation in the CDM domain produced two
alternate SP-A isoforms, SP-A1 and SP-A2, and changes in the
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TABLE 6 | Parameters of human SP-A binding to murine alveolar macrophages.
SP-A1 SP-A2
Genotype Bmax Kd (nM) h Bmax Kd (nM) h
SP-A+/+ 3.60 ± 1.32 5.14 ± 3.13 1.88 ± 2.3 16.57 ± 1.30 5.00 ± 0.70 1.88 ± 0.49
SP-A−/− No binding – – 8.43 ± 1.40 7.04 ± 3.00 0.93 ± 0.20
SP-A−/−,Sftpa2(1A0) 5.60 ± 0.54 5.29 ± 0.17 1.76 ± 0.47 20.37 ± 1.31 5.00 ± 0.67 1.36 ± 0.22
SP-A−/−,Sftpa1(6A2) 6.84 ± 1.45 12.96 ± 7.01 0.89 ± 0.17 8.10 ± 0.45 2.80 ± 0.47 1.25 ± 0.21
SP-A1+EDTA SP-A2+EDTA
SP-A+/+ No binding – – 3.00 ± 0.42 9.20 ± 2.52 1.29 ± 0.27
SP-A−/− No binding – – 2.50 ± 0.28 10.82 ± 2.04 1.53 ± 0.26
SP-A−/−,Sftpa2(1A0) 1.19 ± 0.33 17.63 ± 9.85 1.07 ± 0.23 5.32 ± 1.60 21.40 ± 11.95 1.14 ± 0.23
SP-A−/−,Sftpa1(6A2) 1.66 ± 0.62 26.20 ± 21.13 0.92 ± 0.19 2.60 ± 0.28 10.26 ± 2.16 1.24 ± 0.17
TABLE 7 | Parameters of human SP-A binding to human alveolar macrophages.
AM source SP-A1 SP-A2
Bmax Kd (nM) h Bmax Kd (nM) h
Newborn AM 5.74 ± 0.75 9.55 ± 2.84 1.06 ± 0.17 10.23 ± 1.30 6.42 ± 0.70 0.91 ± 0.49
Adult AM 9.30 ± 0.34 7.02 ± 0.40 2.61 ± 0.34 31.12 ± 2.62 7.46 ± 1.10 1.73 ± 0.34
SP-A1+EDTA SP-A2+EDTA
Newborn AM 1.60 ± 0.24 4.43 ± 1.25 1.72 ± 0.90 2.74 ± 0.27 5.94 ± 1.42 1.02 ± 0.16
Adult AM 7.49 ± 2.22 15.23 ± 6.46 1.78 ± 0.65 14.36 ± 0.71 9.80 ± 0.73 1.97 ± 0.20
CRD produced four variants, two for SP-A1 and two for SP-A2.
These demarcate differences in ligand-induced modulation of
receptor occupancy on AMs in vivo. In the present study we
studied two of the CRD variants, one for SP-A1 (6A2) and
one for SP-A2 (1A0). The amino-terminal half of the CDM
of rat SP-A (Figure 1B) contains contiguous 85RGDKGE90
integrin binding motifs that are partially conserved in mouse
SP-A with a corresponding 85HGDKGE90 but diverged in
human SP-A with 85CGEKGE90 in SP-A1 and 85RGEKGE90
in SP-A2 (Figure 1B). Although RGD, HGD, and KGE motifs
are well-known for binding to integrins (78, 79), other studies
have reported interactions with the C2 membrane binding
domain of phospholipases and other proteins (80–82). The
interaction of this motif with SP-R210 remains to be determined.
Evolutionary adaptation in the CRD domain of both isoforms
introduced a natural R197A substitution between rodent and
human SP-A2 (1A0) (Figure 1A). This substitution appears
to isolate the impact of post-translational hydroxylation of
proline on receptor occupancy by altering the interaction of the
CRD domain with solvent and topology of Ca++ coordination
residues in the CLL. These CDM and CRD adaptations may
compensate for differences in dietary requirements for ascorbic
acid and proline hydroxylation between rodents and humans
(83). The present findings, however, indicate that single
amino acid changes can profoundly affect CRD conformation,
domain-domain interaction, and binding to macrophage
receptors via CDM and CRD domains. In this regard, the
CRD domain of human SP-A1 and SP-A2 is polymorphic
resulting in diverse allelic combinations of SP-A1 and SP-A2
variants. Both coding and non-coding polymorphisms have
been associated with increased or decreased risk to lung disease
in numerous studies (77, 84). Understanding the structure-
function relationship on human SP-A isoforms will require
better understanding of copy number variation and biochemical
characterization of polymorphic chain composition of SP-A1 and
SP-A2 isoforms.
SP-A plays versatile roles in host defense through concomitant
interactions with pathogens, surfactant lipids, and immune
cells (1). SP-A controls the direction of macrophage activation,
suppressing or inducing macrophage inflammatory responses
as well as polarization toward either M1 or M2 types of
differentiation and intrinsic regulation of innate immune
receptor expression and function through the coordination of
two SP-R210 isoforms (14, 27, 29, 33, 85, 86). Given present
evidence that the SP-A CLL interacts with pattern recognition
receptors (87), a distinct receptor binding site could be used
to facilitate transfer of diverse SP-A cargo to innate immune
receptors on macrophages. The SP-A structural determinants
that differentially modulate receptor occupancy and signaling in
AMs in the face of diverse immune challenges in the local lung
microenvironment are subject to extensive investigation at the
molecular level.
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CONCLUSIONS
Human SP-A isolated from alveolar proteinosis fluid has
been utilized extensively to discern function utilizing rodent
alveolar macrophages without knowledge of the donor SP-A
genotype. These studies generated invaluable information but
also produced controversial as well as disparate results on SP-A
immune functions and identity of SP-A receptors. The present
findings in mouse AMs exposed to human SP-A isoforms not
only support cross-species conservation and validity of ex vivo
studies but also indicate genetic origin of SP-A preparations
as an important variable in understanding versatility of SP-A
function in humans. In this regard, the presence of SP-A1 may
attenuate receptor occupancy, which likely regulates functional
interactions with AMs at physiologically high levels of SP-A
at homeostasis. Furthermore, although the present studies are
limited by the small numbers of samples, the findings in newborn
and adult AMs suggest increased receptor complexity that is
developmentally regulated in humans.
Finally, our simulation and binding data indicate that the
auxiliary ion coordination loop encompassing the conserved
E171 residue may comprise a conserved site of interaction
with macrophages, and SP-R210 specifically, that merits further
investigation to discern conserved and divergent SP-A functions
between species. In this context, we recognize that there are
limitations inherent to MD simulations that impact the behavior
of ions. MD simulations, however, have the potential to unveil
how structural differences alter dynamic properties that are
crucial for understanding the interplay of structure and function
as well as providing guidelines for experiments. The purpose
of the simulations, however, was not to reproduce the exact
theoretical or experimental ion interactions but instead, to carry
out a comparative study of wild type and mutated structures
and specifically investigate the distances and their stability.
This comparative in silico analysis of the R197A mutant in
combination with our binding results showing that this species
adapted residue modulates binding to the receptor opens exciting
questions on future structure-function studies to understand the
basis of molecular adaptation of the human SP-A molecules.
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